Patients with a prescription for an opioid use disorder medication may have a tough time getting it filled if their pharmacy is in a community that’s racially and economically segregated, according to a new study led by scientists at Oregon State University and Johns Hopkins University.
Corrected: Over a year after FDA rejection, Biohaven claims success in pivotal neurodegenerative disease study
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 24, 2024